Core Viewpoint - Nanjing Noling Biotechnology Co., Ltd. is set to become the first company in the nitric oxide (NO) therapy sector to go public on the Hong Kong Stock Exchange, focusing on innovative medical devices for critical care [2][3]. Company Overview - Founded in April 2018, Noling Biotech specializes in inhaled nitric oxide (iNO) therapy, with its core product aimed at treating pulmonary hypertension and other critical conditions [2][3]. - The company has developed a comprehensive technology platform for NO, covering generation, transmission, detection, storage, and clinical application, making it one of the few globally to achieve full control over the NO technology chain [3][19]. Product and Market Position - Noling's flagship product, iNOwill, is projected to lead the domestic iNO treatment market in 2024, with expected revenue of 45.547 million yuan [3][29]. - The company has five products approved and four in development, with a presence in nearly 700 hospitals across 31 provinces in China and exports to ten countries [3][24]. Financial Performance - In 2024, the company anticipates revenues of 45.547 million yuan, with a significant portion of its revenue coming from the iNO treatment devices [29][31]. - The company has experienced substantial growth in valuation, increasing from approximately 50 million yuan at the angel round to 1.648 billion yuan in the C round, representing a growth of over 32 times [34]. Investment and Shareholding - Major external shareholders include Lilly Asia Ventures and Northern Light Venture Capital, holding 12.08% and 11.43% of shares, respectively [4]. - The company has completed multiple funding rounds, attracting investments from various venture capital firms and local government funds [34][35]. Industry Context - The global iNO treatment market is projected to grow from 1.02 billion USD in 2024 to 1.64 billion USD by 2030, with a compound annual growth rate of 8.3% [38]. - The shift towards portable, on-demand NO delivery systems is expected to drive market growth, as traditional high-pressure cylinder systems are being replaced [41]. Strategic Direction - Noling aims to expand its indications from pulmonary hypertension to other respiratory diseases such as ARDS and COPD, and to penetrate various healthcare settings from ICUs to home care [42]. - The company is also focused on global market expansion, with plans for FDA submissions for its products in North America and ongoing commercialization efforts in Asia and Europe [42].